| abstract |
This invention relates to a stent device having a polymer coating that contains a TGF-P and / or LCK tyrosine kinase inhibitor represented by a compound of formula I where X is LOH or LZ; L represents (CRR) or (CRR) -Z- (CRR); L is (CRR) -Z- (CRR) or ethenyl; Z represents CH or N; Z represents optionally substituted hydroxycycloalkyl, optionally substituted hydroxycycloalkenyl, optionally substituted hydroxyheterocyclyl, or optionally substituted hydroxyheterocyclenyl; Z represents O, NR, S, SO or SO; Z represents O, NR, S, SO, SO, or a bond; m is 0 or 1; n is 2 or 3 and n + m = 2 or 3; p and q are, independently, 0, 1, 2, 3, or 4, and p + q = 0, 1, 2, 3, or 4 when Z is a bond, and p + q = 0, 1, 2, or 3 when Z is other than communication; r is 2, 3 or 4; its N-oxide, its hydrate, its solvate, its prodrug, or its pharmaceutically acceptable salt. The compound of formula I suppresses growth factor derived from platelets or p56lck tyrosine kinase activity. This invention also relates to the use of a compound of formula I in the manufacture of a stent for inhibiting restenosis, in particular restenosis, resulting from mechanical damage to an artery wall obtained in the treatment of atherosclerotic lesion by angioplasty. |